201 filings
Page 2 of 11
6-K
kjs95rbnnnqmgog7b
22 Jun 23
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
6:41am
6-K
va6qtwf
5 Jun 23
Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant non-small cell lung cancer (NSCLC) cohort
6:04am
6-K
x6k662b b4liragn
23 May 23
Unaudited consolidated statements of comprehensive loss
6:46am
6-K
wx3l0g7my xqf32
22 May 23
Affimed Announces Annual General Meeting of Shareholders
6:49am
6-K
wwrbv rm5qwgkz3akve4
6 Apr 23
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding
5:07pm
S-8
8onu3 lvgp0m
23 Mar 23
Registration of securities for employees
4:53pm
424B5
t7tc2w6 6npas
23 Mar 23
Prospectus supplement for primary offering
4:50pm
6-K
gw19dg4 o4ajmj7dj
23 Mar 23
Affimed Reports 2022 Financial Results and Operational Progress
4:13pm
6-K
77xd6
9 Jan 23
Affimed Reports on Corporate Progress and Provides
6:45am
6-K
jd4 c9xil
12 Dec 22
Affimed Provides Updated Clinical Data from Phase 1/2 Study of
8:15am
6-K
pylq2e84utmp
15 Nov 22
Current report (foreign)
6:42am
6-K
08dhtq uq1jom8
3 Nov 22
Affimed and Artiva Biotherapeutics Announce Partnership to Advance
9:23am
6-K
w17ee672xg333y4ltp
11 Aug 22
Current report (foreign)
6:31am
6-K
38ebxxq z8
23 Jun 22
Current report (foreign)
7:28am
6-K
r57x76v52 x4ezzxqh
1 Jun 22
Current report (foreign)
6:53am
6-K
xw37 vzh9bz
24 May 22
Affimed Announces Annual General Meeting of Shareholders
6:40am
6-K
2a5i vnxnf6s1
18 Apr 22
Current report (foreign)
4:06pm
424B5
hm2tgy7elyf1myh26p
14 Apr 22
Prospectus supplement for primary offering
4:17pm
424B5
w28j2cygrkpnrfvx8f4t
12 Apr 22
Prospectus supplement for primary offering
4:11pm